litlas
Log inCreate account

Heinz‐Josef Lenz

Active 1987–2026

Also published as
Heinz-Josef Lenz · Heinz Josef Lenz · Heinz Josef–Lenz
297
Papers
53,704
Citations
111
h-index
281
i10-index

Citations

Citations per year for Heinz‐Josef Lenz1990: 3 citations1991: 3 citations1992: 1 citations1993: 2 citations1995: 3 citations1996: 5 citations1997: 11 citations1998: 22 citations1999: 26 citations2000: 66 citations2001: 42 citations2002: 74 citations2003: 78 citations2004: 91 citations2005: 112 citations2006: 114 citations2007: 154 citations2008: 231 citations2009: 247 citations2010: 321 citations2011: 242 citations2012: 198 citations2013: 243 citations2014: 282 citations2015: 315 citations2016: 298 citations2017: 416 citations2018: 464 citations2019: 1,882 citations2020: 2,267 citations2021: 2,306 citations2022: 1,903 citations2023: 1,585 citations2024: 2,370 citations2025: 1,207 citations2026: 34 citations1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,737 citing papers, 22.9% of this breakdownChina: 3,351 citing papers, 16.2% of this breakdownItaly: 1,271 citing papers, 6.2% of this breakdownUnited Kingdom: 1,083 citing papers, 5.2% of this breakdownGermany: 948 citing papers, 4.6% of this breakdownFrance: 818 citing papers, 4% of this breakdownJapan: 769 citing papers, 3.7% of this breakdownSpain: 730 citing papers, 3.5% of this breakdownNetherlands: 574 citing papers, 2.8% of this breakdownCanada: 514 citing papers, 2.5% of this breakdownAustralia: 476 citing papers, 2.3% of this breakdownSouth Korea: 422 citing papers, 2% of this breakdown
0%22.9%Other 24.1%

Institutions

Fields

  • Medicine63.1%
  • Biochemistry, Genetics and Molecular Biology27.2%
  • Immunology and Microbiology5%
  • Neuroscience1.1%
  • Engineering0.8%
  • Materials Science0.6%
  • Other2.2%

Topics

  • Colorectal Cancer Treatments and Studies6.9%
  • Cancer Immunotherapy and Biomarkers6.1%
  • Genetic factors in colorectal cancer3.9%
  • Cancer Genomics and Diagnostics3.3%
  • Cancer Cells and Metastasis2.1%
  • Immunotherapy and Immune Responses2%
  • Other75.7%

Coauthors

All papers

Open in search
  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Authors: Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André - The Lancet Oncology 2017 cited by 2,816

  2. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

    Authors: Ryuma Tokunaga, Wu Zhang, Madiha Naseem, Alberto Puccini, Martin D. Berger, Shivani Soni, Michelle McSkane, Hideo Baba, Heinz‐Josef Lenz - Cancer Treatment Reviews 2017 cited by 1,642

  3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Authors: Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz‐Josef Lenz, Richard M. Goldberg, Daniel J. Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent - The Lancet 2012 cited by 2,897

  4. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

    Authors: Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar García-Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Sandzhar Abdullaev, Joseph Gricar, Jean-Marie Ledeine, Michael James Overman, Sara Lonardi - Journal of Clinical Oncology 2021 cited by 671

  5. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

    Authors: Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André - Journal of Clinical Oncology 2018 cited by 2,070

  6. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Authors: Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio García‐Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Éveline Boucher, Marc Peeters, Ben Tran, Heinz‐Josef Lenz, Alberto Zaniboni, Howard S. Höchster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu - New England Journal of Medicine 2015 cited by 1,431

  7. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

    Authors: John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, Elena Élez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios Bekaii‐Saab, Eric Van Cutsem, Marc Peeters, Marc Van den Evnde, Thierry André, Christophe Borg, Matthieu Sarabi, François Ghiringhelli, Benoist Chibaudel, Salvatore Siena, Chiara Cremolini, Maria Giulia Zampino, Elena Élez, Susana R. Keranen, Ramón Salazar, Pilar Alfonso, John H. Strickler, Andrea Cercek, Kimmie Ng, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, David L. Bajor, Tanios Bekaii‐Saab, Olumide B. Gbolahan, Patrick M. Boland, Daniel Berg, Federico Sanchez, Timothy F. Goggins, Federico Sanchez, Howard A. Burris, Johanna C. Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel V.T. Catenacci, Jun Gong, Ignacio Garrido‐Laguna, Gene Grant Finley, Benjamin A. Weinberg, Anthony F. Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher S. Chen, James M. Ford, Madappa N. Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer H. Shao, Scott McKenney, Spencer H. Shao - The Lancet Oncology 2023 cited by 245

  8. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

    Authors: Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke - JAMA 2017 cited by 893

  9. Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy

    Authors: Xiaojing Shi, Qinqin Cheng, Tianling Hou, Menglu Han, Goar Smbatyan, Julie E. Lang, Alan L. Epstein, Heinz‐Josef Lenz, Yong Zhang - Molecular Therapy 2019 cited by 231

  10. Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity

    Authors: Qinqin Cheng, Xiaojing Shi, Menglu Han, Goar Smbatyan, Heinz‐Josef Lenz, Yong Zhang - Journal of the American Chemical Society 2018 cited by 283

  11. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    Authors: Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. Naomi Horiba, Sreenivasa Nattam, Robert Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany Sleckman, Heinz‐Josef Lenz, Patrick J. Stiff, Pankaj Kumar, Peng Xu, Les Henderson, Naoko Takebe, Ravi Salgia, Xi Wang, Walter M. Stadler, Frédéric J. de Sauvage, Hedy L. Kindler - Journal of Clinical Oncology 2015 cited by 544

  12. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Authors: Scott Kopetz, Katherine A. Guthrie, Van K. Morris, Heinz‐Josef Lenz, Anthony M. Magliocco, Dipen M. Maru, Yibing Yan, Richard B. Lanman, Ganiraju C. Manyam, David S. Hong, Alexey V. Sorokin, Chloé E. Atreya, Luis A. Díaz, Carmen J. Allegra, Kanwal Raghav, Stephen E Wang, Christopher H. Lieu, Shannon McDonough, Philip A. Philip, Howard S. Höchster - Journal of Clinical Oncology 2020 cited by 391

  13. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

    Authors: Arvind Dasari, Van K. Morris, Carmen J. Allegra, Chloé E. Atreya, Al B. Benson, Patrick M. Boland, Ki Yong Chung, Mehmet Sitki Copur, Ryan B. Corcoran, Dustin A. Deming, Andrea Dwyer, Maximilian Diehn, Cathy Eng, Thomas J. George, Marc J. Gollub, Rachel Goodwin, Stanley R. Hamilton, Jaclyn F. Hechtman, Howard S. Höchster, Theodore S. Hong, Federico Innocenti, Atif Iqbal, Samuel A. Jacobs, Hagen F. Kennecke, James J. Lee, Christopher H. Lieu, Heinz‐Josef Lenz, O. Wolf Lindwasser, Clara Montagut, Bruno C. Odisio, Fang‐Shu Ou, Laura Porter, Kanwal Raghav, Deborah Schrag, Aaron J. Scott, Qian Shi, John H. Strickler, Alan P. Venook, Rona Yaeger, Greg Yothers, Y. Nancy You, Jason A. Zell, Scott Kopetz - Nature Reviews Clinical Oncology 2020 cited by 365

  14. Quantitative evidence for early metastatic seeding in colorectal cancer

    Authors: Zheng Hu, Jie Ding, Zhicheng Ma, Ruping Sun, José A. Seoane, J. Scott Shaffer, Carlos J. Suarez, Anna S. Berghoff, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Peter Birner, Matthias Preusser, Heinz‐Josef Lenz, Christina Curtis - Nature Genetics 2019 cited by 524

  15. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle

    Authors: Meng Qu, Guoxin Zhang, Han Qu, Alexander Vu, Raymond Wu, Hidekazu Tsukamoto, Zhenyu Jia, Wendong Huang, Heinz‐Josef Lenz, Jeremy N. Rich, Steve A. Kay - National Academy of Sciences, Proceedings of the National Academy of Sciences 2023 cited by 141

  16. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

    Authors: Dirk Arnold, B. Lueza, Jean-Yves Douillard, Marc Peeters, Heinz‐Josef Lenz, Alan P. Venook, Volker Heinemann, Eric Van Cutsem, Jean‐Pierre Pignon, Josep Tabernero, Andrés Cervantes, Fortunato Ciardiello - Annals of Oncology 2017 cited by 836

  17. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

    Authors: Michal A. Stanczak, Shoib Sarwar Siddiqui, Marcel P. Trefny, Daniela S. Thommen, Kayluz Frias Boligan, Stephan von Gunten, Alexandar Tzankov, L. Tietze, Didier Lardinois, Viola Heinzelmann‐Schwarz, Michael von Bergwelt‐Baildon, Wu Zhang, Heinz‐Josef Lenz, Younghun Han, Christopher I. Amos, Mohammedyaseen Syedbasha, Adrian Egli, Frank Stenner, Daniel E. Speiser, Ajit Varki, Alfred Zippelius, Heinz Läubli - Journal of Clinical Investigation 2018 cited by 306

  18. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

    Authors: Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, I. Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J. Han van Krieken, Fortunato Ciardiello - Journal of Clinical Oncology 2015 cited by 800

  19. Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

    Authors: Thierry André, Elena Élez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Méndez, Michael Schenker, Christelle de la Fouchardière, María Luisa Limón, Takayuki Yoshino, Jin Li, Heinz‐Josef Lenz, José Luis Manzano Mozo, Giampaolo Tortora, Rocio García‐Carbonero, Laëtitia Dahan, Myriam Chalabi, Rohit Joshi, Eray Goekkurt, Maria Ignez Braghiroli, Timuçin Çil, Elvis Cela, Tian Chen, Ming Lei, Matthew Dixon, Sandzhar Abdullaev, Sara Lonardi - New England Journal of Medicine 2024 cited by 213

  20. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.

    Authors: Francesca Battaglin, Madiha Naseem, Heinz‐Josef Lenz, Mohamed E. Salem - 2018 cited by 205

  21. B cell and B cell-related pathways for novel cancer treatments

    Authors: Ryuma Tokunaga, Madiha Naseem, Jae Ho Lo, Francesca Battaglin, Shivani Soni, Alberto Puccini, Martin D. Berger, Wu Zhang, Hideo Baba, Heinz‐Josef Lenz - Cancer Treatment Reviews 2018 cited by 262

  22. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes

    Authors: Qinqin Cheng, Zhefu Dai, Goar Smbatyan, Alan L. Epstein, Heinz‐Josef Lenz, Yong Zhang - Molecular Therapy 2022 cited by 83

  23. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

    Authors: Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Neil H Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloé Delépine, Tyler J. Curiel, Justin Stebbing, Heinz‐Josef Lenz, Steven O’Day, Anthony B. El-Khoueiry - Nature Medicine 2024 cited by 110

  24. Molecular insight of regorafenib treatment for colorectal cancer

    Authors: Hiroyuki Arai, Francesca Battaglin, Jingyuan Wang, Jae Ho Lo, Shivani Soni, Wu Zhang, Heinz‐Josef Lenz - Cancer Treatment Reviews 2019 cited by 205